- 1 Full title: High confidence and demand for hepatitis E vaccine during an outbreak in Bentiu,
- 2 South Sudan: A qualitative study
- 3
- 4 **Short title:** High confidence and demand for hepatitis E vaccine in Bentiu, South Sudan
- 5
- 6 Aybüke Koyuncu<sup>1,2\*</sup>, Kinya Vincent Asilaza<sup>3</sup>, John Rumunu<sup>4</sup>, Joseph Wamala<sup>6</sup>, Priscillah Gitahi<sup>3</sup>,
- 7 Zelie Antier<sup>3</sup>, Jetske Duncker<sup>3</sup>, Patrick Nkemenang<sup>3</sup>, Primitive Gakima<sup>5</sup>, Melat Haile<sup>5</sup>, Etienne
- 8 Gignoux<sup>2,5</sup>, Manuel Albela<sup>5</sup>, Frederick Beden Loro<sup>6</sup>, Duol Biem<sup>4</sup>, Monica Rull<sup>5</sup>, Andrew S
- 9 Azman<sup>1,5,7,8</sup>, Iza Ciglenecki<sup>5</sup>, Robin Nesbitt<sup>2</sup>
- 10
- 11 <sup>1</sup>Johns Hopkins University, USA
- 12 <sup>2</sup>Epicentre, France
- 13 <sup>3</sup>Médecins Sans Frontières, South Sudan
- <sup>4</sup>Ministry of Health, South Sudan
- 15 <sup>5</sup>Médecins Sans Frontières, Switzerland
- <sup>6</sup>World Health Organisation, South Sudan
- <sup>17</sup> <sup>7</sup>Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva,
- 18 Switzerland
- <sup>8</sup>Division of Tropical and Humanitarian Medicine, Geneva University Hospitals, Geneva,
- 20 Switzerland
- 21
- 22 \*Corresponding author
- 23 Email: akoyunc1@jhu.edu
- 24

#### 25

## 26 Abstract

Introduction: In 2021 in response to an outbreak of hepatitis E in Bentiu internally
displaced persons camp the South Sudanese Ministry of Health with support from Médecins
Sans Frontières implemented the first-ever mass reactive vaccination campaign with HEV239
(Hecolin; Innovax, Xiamen, China). As part of an evaluation of the feasibility of hepatitis
vaccination as part of an epidemic response, we conducted qualitative research to assess
knowledge, attitudes, and practices related to hepatitis E and the hepatitis E vaccine.

33 **Methods:** We conducted 8 focus group discussions (FGDs) with community leaders, the 34 general population of vaccine-eligible adults, vaccine-eligible pregnant women (vaccinated and 35 non-vaccinated), and healthcare workers. FGDs were separate by gender and were audio 36 recorded, transcribed, and translated to English by trained research assistants. Two coders 37 used inductive thematic analysis to organize emergent themes.

**Results:** Data were collected in November 2022. Most individuals had personal 38 39 experiences with hepatitis E. Hepatitis E was perceived as a dangerous disease, and almost 40 everyone was knowledgeable about transmission pathways. Participants believed children, 41 pregnant women, and the elderly were the highest risk groups. Participants frequently made 42 requests for additional hepatitis E vaccination campaigns and expanded eligibility criteria for 43 vaccination. The primary barriers to vaccination were practical issues related to being away 44 from the camp at the time of the campaign, but participants shared that some in the community 45 were unvaccinated due to fears about injections, social pressure, misinformation about side 46 effects such as infertility, concerns about why some groups were eligible for vaccination and not 47 others (e.g. young children), and a lack of information about the vaccine/vaccination campaigns.

48 **Conclusion:** Personal experiences with hepatitis E illness, perceived severity of illness,

- 49 and confidence in organizations recommending the vaccine were drivers of high demand for
- 50 hepatitis E vaccines in the first-ever use of the vaccine in an outbreak setting.
- 51
- 52
- 53
- •••
- 54
- 54
- 55
- 55
- 56

# 57 Introduction

58

Hepatitis E genotypes 1 and 2 cause over 3 million symptomatic cases of acute viral hepatitis each year with case fatality risk as high as 65% among pregnant women [1–3]. Large outbreaks of hepatitis E virus (HEV) genotypes 1 and 2 occur due to fecal contamination of drinking water, and at least 1 large-scale outbreak with over 5,000 suspected hepatitis E cases has occurred in every decade since 1988 [4]. While outbreaks occur in resource-limited settings throughout Africa and Asia, refugees and internally displaced persons are at heightened risk for outbreaks due to overcrowding and poor access to safe water, sanitation, and hygiene (WASH) [1,5].

66

67 One potential tool for HEV outbreak control is a recombinant vaccine, HEV239 (Hecolin;

68 Innovax, Xiamen, China), which has been proven to be safe and efficacious in individuals 16-64

69 years old [6]. The vaccine is licensed only in China and Pakistan and has not been 70 recommended by the World Health Organization (WHO) for routine use in HEV-endemic 71 countries, largely due to a lack of epidemiologic data in the general population [1]. Despite a 72 lack of data to justify routine use of the vaccine, in 2015 WHO recommended the vaccine be 73 considered as a strategy to mitigate or prevent outbreaks [1]. While the current vaccine's 3-dose 74 schedule given across 6 months is not ideal for rapid deployment in outbreak settings [7]. 75 multiyear protracted HEV epidemics suggest the potential for even a 6-month regimen to 76 substantially prevent morbidity and mortality, particularly among high-risk groups such as 77 refugees and pregnant women.

78

79 In Bentiu IDP camp, hepatitis E cases have been reported since 2014 with large outbreaks 80 occurring in 2015-2016 and again in 2019. Between October 2014 and April 2022 there were 81 2,227 confirmed cases of hepatitis E in Bentiu camp. In response, the South Sudanese Ministry 82 of Health (MOH) in partnership with MSF implemented the first-ever vaccination campaign for 83 hepatitis E in the context of an outbreak beginning in March 2022. The campaign targeted 84 individuals 16-40 years old residing in Bentiu camp, including pregnant women. The campaign 85 took place in three rounds in March, April and October 2022 [8]. In parallel, MOH and MSF 86 implemented operational research to understand the effectiveness, safety, and feasibility of 87 vaccination against hepatitis E. As part of this research, a vaccination coverage survey was 88 conducted immediately after the third and final vaccination round. Coverage with at least one 89 dose of the vaccine in the target population was 86% (95% CI: 84-88), and the most frequent 90 reasons for non-vaccination were physical absence (60%) and fears and concerns (18%) [9]. 91 Here we report findings from the qualitative component of the study aimed at understanding 92 community perspectives on hepatitis E, hepatitis E vaccine, and barriers and facilitators of 93 vaccine uptake.

#### 94

#### 95

# 96 Materials and methods

97

## 98 Setting

99 Bentiu internally displaced persons (IDP) camp was established in 2014 as a Protection of

100 Civilians site at a United Nations Mission in South Sudan base in response to conflict in Unity

101 State. The camp has expanded since 2014 and the total camp population in 2022 was

102 approximately 112,000 residents.

103

### 104 **Participants**

105 We recruited community leaders, the general population of vaccine-eligible adults(i.e. 16-40 106 years, resident of Bentiu IDP camp), vaccine-eligible pregnant women (vaccinated and non-107 vaccinated), and healthcare workers to participate in focus group discussions (FGDs). The 108 general population was recruited using convenience sampling in each camp sector from 109 individuals already participating in research on vaccine coverage while pregnant women were 110 recruited from individuals already participating in research on vaccine safety. Community 111 leaders and medical staff were approached separately for recruitment. We asked the Camp 112 High Commission to recommend community leaders and asked managers at health facilities to 113 recommend medical staff working with hepatitis E patients.

114

## 115 Data collection

Data were collected in November 2022. We selected the Behavioral and Social Drivers of
Vaccination (BeSD) framework [10] *a priori* to develop FGD guides and organize emerging

118	themes for knowledge, attitudes, and practices about hepatitis E, perceptions about the hepatitis
119	E vaccine, and barriers and facilitators of hepatitis E vaccine uptake. The BeSD framework is a
120	theory-based framework for understanding individual and community-level drivers of vaccination
121	uptake that is organized into four domains: thinking and feeling, social processes, motivation,
122	and practical issues (Fig 1).
123	
124	Figure 1 The behavioral and social drivers of vaccination (BeSD) framework. Based on the BeSD working group (10) and adapted
125	from Brewer et al. [11]
126	
127	FGDs were conducted separately by population type and gender except for healthcare workers.
128	FGDs were conducted in Nuer or English and were audio recorded, transcribed, and translated
129	to English.
130	

### 131 Analysis

132 Within domains of the BeSD framework, two coders (AK and RN) used inductive thematic 133 analysis to iteratively read transcripts and code the text in the data. Emergent key themes and 134 codes were entered into a codebook, and codebooks and the categorization of data were 135 compared for 2 FGDs. We used a negotiated agreement approach to assess intercoder 136 reliability [12], with differences in coding adjudicated by discussion and consensus between 137 coders. Once the emergent codes and themes were standardized, both coders independently 138 coded the text in the remaining data using Nvivo software (QSR International, Melbourne, 139 Australia). Once the emergent codes and themes were standardized, both coders independently 140 coded the text in the remaining data using Nvivo software (QSR International, Melbourne, 141 Australia).

142

### 144 Ethics

145 Ethical approval was granted from the MSF Ethical Review Board (ERB) and by the South

- 146 Sudan Ministry of Health Research Ethics Board as part of the study protocol titled:
- 147 "Effectiveness, safety and feasibility of recombinant hepatitis E vaccine HEV 239 (Hecolin)
- 148 during an outbreak of hepatitis E in Bentiu, South Sudan" (MSF ERB #2167 and RERB-MOH #
- 149 54/27/09/2022). All participants provided verbal informed consent before participating in a FGD.

150

## 151 **Results**

152 We conducted 8 FGDs with 6-8 participants each (48-64 total participants): 2 FGDs with

153 community leaders, 2 FGDs with the vaccinated general population, 2 FGDs with the

154 unvaccinated general population, 1 FGD with healthcare workers, and 1 FGD with pregnant

155 women. Participants from the general population were aged 18-40 while community leaders and

156 healthcare workers included participants outside of the vaccine-eligible range. Emergent themes

- 157 were consistent by participant type and gender.
- 158

### 159 Thinking and feeling

All population types were very knowledgeable about hepatitis E symptoms, transmission pathways, and prevention methods. The most frequently mentioned symptoms associated with hepatitis E were yellow eyes, fever, and dark urine. Some participants also mentioned yellow or "light" skin and general weakness of the body. Cleanliness and WASH were frequently reported as key prevention strategies. Many respondents felt it was difficult to prevent HEV infection with vaccine alone because of the crowded conditions in the camp:

167 "All toilets are full and we are trying to advice people to be vaccinated yet the problem of toilets 168 is very dangerous one." -Male community leader 169 170 Most participants had high perceived risk of being infected with hepatitis E and perceived 171 hepatitis E as a dangerous and serious infection. Hepatitis E was perceived as more severe in 172 comparison to other infectious diseases such as malaria: 173 174 "HEP E is dangerous compared with malaria; malaria can be treated but HEP E can take long to 175 be treated." -Male community leader 176 177 Other reasons for perceiving hepatitis E as more serious compared to other infections included 178 potential impacts of infection on family finances (e.g if the breadwinner is infected), the potential 179 for infection to be fatal, and knowledge that there is no existing treatment. Many individuals 180 described traditional healing methods for hepatitis E that were used in their villages and also in 181 the camp which involve beating the infected person with a hot metallic stick. 182 183 "During the village life, when you are HEP E positive, the only thing people do is beat you with 184 metallic stick put on fire for you to get well, but now we have the vaccine given by MSF freely 185 without paying any single money, when you are beaten with that thing put on fire, you will feel 186 pain at the same time." 187 -Pregnant female community member 188 189 Most individuals had personal experiences with hepatitis E including being infected themselves 190 or having a family member, neighbor, or community member that had been symptomatically 191 infected: 192

193	"In the past, during the time of village life, my sister was infected with HEP E, because there
194	were no vaccine, she died, but now the vaccine is brought by MSF"
195	-Pregnant female community member
196	
197	"Community leaders like the vaccine because they have seen the how worse is HEP E in the
198	past and it infected some of them, some of them were involved during the campaign too."
199	-Female community leader
200	
201	Children, pregnant women, and the elderly were consistently identified as high-risk groups for
202	HEV infection and/or severe outcomes. Children were perceived as being at high-risk because
203	they play in dirty areas in the camp, are more likely to practice open defecation and don't know
204	how to take care of themselves, have weak immune systems, and because they forget
205	instructions from parents (e.g. to not play in dirty areas) and can't communicate symptoms when
206	they are ill. Many participants questioned the eligibility criteria for vaccination and requested that
207	future campaigns include children and elderly in the target population:
208	
209	"In this camp, many people are infected, but mostly children. My question is that, why MSF is
210	not bring the vaccine for children? And this disease is affecting children serious through dirty
211	water and dirty playing in dirty environment."
212	-Male community leader
213	
214	Participants were aware of the risk of severe outcomes among pregnant women, and the elderly
215	were perceived as a high-risk group for severe outcomes due to weakened immune systems.
216	
217	"When this disease infect the pregnant mother, its not easy for such a mother to survived."
218	-Healthcare worker

219

220 Participants had high confidence in vaccine effectiveness and benefits, vaccine safety, and the 221 organizations recommending the vaccine. Most participants believed it was safe for women to 222 receive the vaccine during pregnancy, though some unvaccinated males acknowledged not 223 knowing if the vaccine was safe for pregnant women. Many participants reported positive 224 impacts of the vaccine campaign such as a perceived reduction in the incidence of hepatitis E. 225 Participants mentioned some community members refused the vaccine due to low knowledge 226 about the importance of the vaccine and rumors about vaccine safety circulating in the 227 community (e.g. fears about infertility following vaccination), but did not report being personally 228 concerned about benefits, safety, or side effects. Some participants reported mild side effects 229 after vaccination such as headaches or fever that cleared in a few days. Some vaccinated 230 individuals reported fear of injections as a personal barrier to vaccination that they overcame. 231 Others mentioned concerns about eligibility as a reason for non-vaccination among community 232 members:

233 "Some people refused the vaccine because they said that why MSF is vaccinating some group234 and leave others to be killed by the disease? Some refused for that reason."

235

-Male community leader

#### 236 Social processes

Most individuals were in support of vaccination and had been vaccinated. Individuals in the general population perceived that most of their community and religious leaders were in support of vaccination, and had high respect for healthcare workers recommending and providing vaccines:

241

242	"We trust also the people who offered to us the vaccine because they are the members of this
243	community"
244	-Vaccinated female community member
245	
246	Trusted relationships with vaccinators and organizations promoting the vaccine were influential
247	in the decision to get vaccinated. Participants reported trusting the vaccine and vaccinators
248	because the vaccine was brought by doctors, the vaccine was brought by MSF, and because
249	the government permitted the vaccination campaign:
250	
251	"As other people talk about it before, this vaccine is very saved for the community because it
252	was brought by doctors from MSF, if we get it from other sources, we will never trust the vaccine
253	at all, if bush men come and tell us about this vaccine, we will never accepted to be vaccinated."
254	-Female community leader
255	
256	Though decision-making was not mentioned explicitly in all FGDs, some participants mentioned
257	the final person to tell whether family members should be vaccinated or not was either the father
258	or mother of the family. Some participants mentioned pressure from other community members
259	to refuse vaccination and circulating rumors about side effects such as infertility and an
260	increased risk of getting other diseases.
261	
262	Motivation
202	

Individuals were highly motivated to get vaccinated. There were frequent requests for additional
hepatitis E vaccination campaigns in the future and expanded age and geographic eligibility in
future campaigns:

- 267 *"My question is about those who are living outside the camp, is there any mean for this to get*
- the vaccine? Remember these people are part of this community."
- 269

-Male community leader

270

### 271 **Practical issues**

- 272 Key facilitators of vaccination were that the vaccine was available free of charge and that
- 273 vaccinators went to all areas of the camp. The primary barrier to vaccination among
- 274 unvaccinated adults was being away from the camp at the time of the campaign:
- 275
- 276 "I was not vaccinated because I was far away from the camp during the vaccination, so I was
- 277 unlucky, my appeal to MSF is if there is still vaccine remain, we should be considered."
- 278 -Unvaccinated female community member
- 279
- 280 Some participants also reported a lack of information about the vaccine and the second and
- third rounds of the vaccination campaign as a barrier to vaccine uptake.
- 282

# 283 **Discussion**

284 Our study identified high demand for hepatitis E vaccines among residents of Bentiu IDP camp. 285 following the first-ever use of the vaccine in an outbreak setting. Personal experiences with 286 hepatitis E illness, the perceived severity of illness, and high confidence in the healthcare 287 providers and organizations recommending and providing the vaccine were key facilitators of 288 vaccine uptake. Perceptions about hepatitis E and the hepatitis E vaccine in our study were 289 consistent by vaccination status, gender, and population type, with the consistency of key 290 themes suggesting data saturation. For example, even unvaccinated adults in our study 291 reported predominantly positive perceptions about the vaccine and asked for additional

opportunities to be vaccinated. While improvements to comprehensive WASH infrastructure are
 needed for long-term control of hepatitis E and other pathogens as noted by community
 members, we identified high demand for hepatitis E vaccines as a tool for prevention and
 control of hepatitis E outbreaks.

296

297 During the second and third rounds of the campaign, the vaccine was offered to anyone within 298 the target group (16-40 years old and residence in Bentiu IDP camp), regardless of whether 299 they received previous doses or not (8). The campaign also had a longer duration than most 300 reactive vaccination campaigns: each round of the campaign lasted more than a week, and the 301 final round lasted more than 2 weeks. Despite these attempts to improve vaccine access, the 302 primary self-reported barrier to vaccine uptake was being away from the camp at the time of the 303 campaign. Our qualitative findings are consistent with the quantitative coverage survey 304 conducted in Bentiu and with findings about primary reasons for non-vaccination in preventative 305 and reactive vaccination campaigns with oral cholera vaccines in various settings [13–15]. The 306 population in Bentiu IDP camp, like many other camp settings, is highly mobile and spends long 307 periods of time outside of the camp. Expanding access to vaccines beyond short-duration 308 campaigns can improve vaccine uptake and increase the likelihood of sustainably maintaining 309 coverage in highly mobile populations such as IDPs. Additional research is needed to explore 310 the potential costs and benefits of vaccination strategies such as extending the duration of the 311 campaign, offering the vaccine to all new camp entries, or routinely offering the vaccine in 312 health facilities. The possibility of implementing these strategies for hepatitis E vaccine is further 313 complicated by Hecolin's bulky, single-dose, pre-filled glass syringes which introduce additional 314 challenges for transport, storage, and waste management.

315

Children and the elderly were consistently identified as high-risk groups for HEV infection and
severe outcomes by the community in Bentiu but were ineligible for vaccination in the campaign.

318 For some individuals, the exclusion of children and the elderly from the campaign contributed to 319 vaccine refusal for themselves. The age target for the campaign (16-40 years) was chosen 320 because the vaccine is not currently registered for use in children younger than 16 years and 321 due to limited doses of the vaccine the upper limit was chosen based on the lower attack rate 322 for hepatitis E among older adults in the camp (8). Notably, perceptions about children as a 323 high-risk group for infection are mirrored in surveillance data on hepatitis E in the camp (68% of 324 confirmed hepatitis E cases based on rapid diagnostic tests between October 2014 and April 325 2022 were aged 10 years or younger (unpublished data)). Additional research is needed to 326 understand the role of children in HEV outbreaks, the safety and efficacy of the vaccine in 327 children, and the potential value of expanding age-eligibility for the vaccine.

328

329 Even amongst unvaccinated participants, we identified few participants with negative views 330 about the vaccine. This may be because the primary barrier to vaccination was being away from 331 the camp. Though not mentioned explicitly by participants in our study, it is also possible that 332 individuals who previously refused the vaccine may have changed their views after witnessing 333 the safety and benefits of the vaccine in their community. Individuals who agreed to participate 334 in this study also may have been more likely to have positive views about the vaccine compared 335 to the general population in Bentiu, and may have been more likely to report positive views 336 during FGDs due to social desirability bias. In an effort to reduce social desirability bias we 337 asked participants to share community perceptions in addition to personal perceptions. Our 338 findings are also consistent with anecdotal data from staff involved in the vaccination campaign 339 as well as results from the coverage assessment which demonstrated high uptake of the 340 vaccine (9). Studies on the acceptability of hepatitis E vaccines are limited, and vaccine 341 confidence can depend on disease-specific knowledge, attitudes, and practices. However, our 342 findings that perceived severity of hepatitis E was a key facilitator for high vaccine confidence 343 and uptake are consistent with qualitative findings from Juba, South Sudan examining drivers of

high oral cholera vaccine uptake during a humanitarian crisis [16]. Our findings may not be
generalizable to outbreak settings with limited historical outbreaks of hepatitis E or to settings
where trusted relationships with MSF and/or the government are lacking. However, our findings
underscore the importance of building trust with communities before, during, and after outbreaks
as a strategy for building vaccine confidence.

349

# 350 Conclusion

351 Hepatitis E is a known and feared disease among the population, and vaccination against it was

a widely accepted and sought-after method of preventing it. Cultivating trusted relationships with

353 communities over time can help individuals overcome common barriers to vaccine confidence.

354 Addressing practical issues related to being away from the camp at the time of the campaign

355 can improve coverage in future campaigns.

356

# 357 Acknowledgments

358 We would like to thank the MSF hepatitis E vaccination and hospital study teams in Bentiu for

their support in implementing the campaign and operational research, as well as the study

360 participants for sharing their perspectives and experiences.

361

# 362 **References**

363

1. World Health Organization. Hepatitis E vaccine: WHO position Paper. 2015 pp. 185–200.

- 365 2. Kamar N, Bendall R, Legrand-Abravanel F, Xia N-S, Ijaz S, Izopet J, et al. Hepatitis E. The
- 366 Lancet. 2012;379: 2477–2488. doi:10.1016/S0140-6736(11)61849-7

367	3.	Amanya G, Kizito S, Nabukenya I, Kalyango J, Atuheire C, Nansumba H, et al. Risk
368		factors, person, place and time characteristics associated with Hepatitis E Virus outbreak
369		in Napak District, Uganda. BMC Infect Dis. 2017;17. doi:10.1186/s12879-017-2542-2
370	4.	Koyuncu A, Mapemba D, Ciglenecki I, Gurley ES, Azman AS. Setting a Course for
371		Preventing Hepatitis E in Low and Lower-Middle-Income Countries: A Systematic Review
372		of Burden and Risk Factors. Open Forum Infectious Diseases. 2021;8: ofab178.
373		doi:10.1093/ofid/ofab178
374	5.	Rein DB, Stevens GA, Theaker J, Wittenborn JS, Wiersma ST. The global burden of
375		hepatitis E virus genotypes 1 and 2 in 2005. Hepatology. 2012;55: 988–997.
376		doi:10.1002/hep.25505
377	6.	Zhu F-C, Zhang J, Zhang X-F, Zhou C, Wang Z-Z, Huang S-J, et al. Efficacy and safety of
378		a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-
379		blind placebo-controlled, phase 3 trial. Lancet. 2010;376: 895–902. doi:10.1016/S0140-
380		6736(10)61030-6
381	7.	Azman A.S., Bouhenia M., Iyer A.S., Rumunu J., Deng L.L., Wamala J.F., et al. High
382		hepatitis e seroprevalence among displaced persons in south sudan: Evidence of
383		undetected transmission and implications for vaccination. American Journal of Tropical
384		Medicine and Hygiene. 2016;95: 593. doi:10.4269/ajtmh.abstract2016
385	8.	Ciglenecki I, Rumunu J, Wamala JF, Nkemenang P, Duncker J, Nesbitt R, et al. The first
386		reactive vaccination campaign against hepatitis E. The Lancet Infectious Diseases.
387		2022;22: 1110–1111. doi:10.1016/S1473-3099(22)00421-2
388	9.	Nesbitt RC, Asilaza VK, Gignoux E, Koyuncu A, Gitahi P, Nkemenang P, et al. Vaccination

389 coverage and adverse events following a reactive vaccination campaign against hepatitis E

in Bentiu displaced persons camp, South Sudan. PLoS Negl Trop Dis. 2024;18: e0011661.

- 391 doi:10.1371/journal.pntd.0011661
- 392 10. Behavioral and Social Drivers of Vaccination (BeSD) The Vaccination Demand Hub. 7 Jul
- 2022 [cited 1 Jun 2023]. Available: https://demandhub.org/behavioral-and-social-drivers-of vaccination-besd/
- 395 11. Brewer NT, Chapman GB, Rothman AJ, Leask J, Kempe A. Increasing Vaccination:
  396 Putting Psychological Science Into Action. Psychol Sci Public Interest. 2017;18: 149–207.
- 397 doi:10.1177/1529100618760521
- 398 12. Campbell JL, Quincy C, Osserman J, Pedersen OK. Coding In-depth Semistructured

399 Interviews: Problems of Unitization and Intercoder Reliability and Agreement. Sociological

400 Methods & Research. 2013;42: 294–320. doi:10.1177/0049124113500475

401 13. Luquero FJ, Grout L, Ciglenecki I, Sakoba K, Traore B, Heile M, et al. First Outbreak


402 Response Using an Oral Cholera Vaccine in Africa: Vaccine Coverage, Acceptability and

- 403 Surveillance of Adverse Events, Guinea, 2012. PLOS Neglected Tropical Diseases.
- 404 2013;7: e2465. doi:10.1371/journal.pntd.0002465
- 405 14. Massing LA, Aboubakar S, Blake A, Page A-L, Cohuet S, Ngandwe A, et al. Highly

406 targeted cholera vaccination campaigns in urban setting are feasible: The experience in

- 407 Kalemie, Democratic Republic of Congo. PLOS Neglected Tropical Diseases. 2018;12:
- 408 e0006369. doi:10.1371/journal.pntd.0006369
- 409 15. Ngwa MC, Alemu W, Okudo I, Owili C, Ugochukwu U, Clement P, et al. The reactive
- 410 vaccination campaign against cholera emergency in camps for internally displaced
- 411 persons, Borno, Nigeria, 2017: a two-stage cluster survey. BMJ Glob Health. 2020;5:
- 412 e002431. doi:10.1136/bmjgh-2020-002431

- 413 16. Peprah D, Palmer JJ, Rubin GJ, Abubakar A, Costa A, Martin S, et al. Perceptions of oral
- 414 cholera vaccine and reasons for full, partial and non-acceptance during a humanitarian
- 415 crisis in South Sudan. Vaccine. 2016;34: 3823–3827. doi:10.1016/j.vaccine.2016.05.038



medRxiv preprint doi: https://doi.org/10.1101/2024.06.25.24309497: this version posted June 26, 2024. The copyright holder for this preprint (which was Agreen in perpetuity) is the Buthon/funder, who has granted medRxiv@license a classical and adapted It is made available under a CC-BY 4.0 International license .

from Brewer et al. [11]

